Clinical Trial Update: Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging [Phase 2]

View source ↗

Summary

Phase 2 trial assessing MRI for early detection of trastuzumab-related cardiac toxicity in breast cancer patients; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Left Ventricular Dysfunction

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Centre Francois Baclesse | Conditions: Cancer, Breast, LV Dysfunction | Phase 2 | Status: TERMINATED